Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Phase II Study of TS-142 in Patients with Insomnia
jRCT2080225269Phase 2Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in subjective sleep latency (sSL) based on sleep diary. Started Jul 2020; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2080225269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225269.